Argenica Therapeutics Ltd has released a press release.
Successful Completion of Phase 1 Clinical Trial Dosing
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- SRC Approves Commencement Of Fourth And Final Cohort Dosing
- Phase 1 Clinical Trial Progress Update
- Safety Review Committee Approves Third Cohort Commencement
- Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial
- Safety Review Committee Approves Second Cohort
Later from Argenica Therapeutics
- Argenica Awarded $1.2m CRC-P Grant for TBI Project
- Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers
- Non-Dilutive Funding Received to Progress Alzheimers Studies
- Interim Phase 1 Safety Report Confirms Safety of ARG-007
- Significant Non-Dilutive Funding For Preclinical HIE Studies
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics